Published in Community Genet on March 26, 2008
SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res (2009) 1.46
Risk, reward, and the double-edged sword: perspectives on pharmacogenetic research and clinical testing among Alaska Native people. Am J Public Health (2013) 0.91
Pharmacogenetics in the brazilian population. Front Pharmacol (2010) 0.88
Pharmacogenetics in American Indian populations: analysis of CYP2D6, CYP3A4, CYP3A5, and CYP2C9 in the Confederated Salish and Kootenai Tribes. Pharmacogenet Genomics (2013) 0.86
Pharmacogenetic research in partnership with American Indian and Alaska Native communities. Pharmacogenomics (2014) 0.83
Ethics and Community Involvement in Syntheses Concerning American Indian, Alaska Native, or Native Hawaiian Health: A Systematic Review. AJOB Empir Bioeth (2014) 0.75
Effects of 22 novel CYP2D6 variants found in Chinese population on the metabolism of dapoxetine. Drug Des Devel Ther (2016) 0.75
Partnership with the Confederated Salish and Kootenai Tribes: Establishing an Advisory Committee for Pharmacogenetic Research. Prog Community Health Partnersh (2016) 0.75
The Affymetrix DMET Plus platform reveals unique distribution of ADME-related variants in ethnic Arabs. Dis Markers (2015) 0.75
International network of cancer genome projects. Nature (2010) 20.35
American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin (2007) 12.19
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med (2005) 8.77
Ethical and practical guidelines for reporting genetic research results to study participants: updated guidelines from a National Heart, Lung, and Blood Institute working group. Circ Cardiovasc Genet (2010) 6.74
Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA (2002) 5.26
An unwelcome side effect of direct-to-consumer personal genome testing: raiding the medical commons. JAMA (2008) 5.25
Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA (2006) 4.87
Offering individual genetic research results: context matters. Sci Transl Med (2010) 4.51
Global epidemiology of hepatitis B virus. J Clin Gastroenterol (2004) 4.48
American Cancer Society guidelines for breast cancer screening: update 2003. CA Cancer J Clin (2003) 4.43
Actionable, pathogenic incidental findings in 1,000 participants' exomes. Am J Hum Genet (2013) 4.06
A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood (2008) 4.02
Reconsidering the family history in primary care. J Gen Intern Med (2004) 3.50
Genomic research and wide data sharing: views of prospective participants. Genet Med (2010) 3.45
National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer. Ann Intern Med (2012) 3.44
Return of individual research results from genome-wide association studies: experience of the Electronic Medical Records and Genomics (eMERGE) Network. Genet Med (2012) 3.29
Glad you asked: participants' opinions of re-consent for dbGap data submission. J Empir Res Hum Res Ethics (2010) 3.29
Potential for genetics to promote public health: genetics research on smoking suggests caution about expectations. JAMA (2006) 3.20
ASHG Statement* on direct-to-consumer genetic testing in the United States. Obstet Gynecol (2007) 3.19
Newborn screening technology: proceed with caution. Pediatrics (2006) 2.54
Warfarin pharmacogenetics. Pharmacotherapy (2008) 2.50
Chlorhexidine compared with povidone-iodine solution for vascular catheter-site care: a meta-analysis. Ann Intern Med (2002) 2.43
Science and regulation. Regulating direct-to-consumer personal genome testing. Science (2010) 2.40
A formal risk-benefit framework for genomic tests: facilitating the appropriate translation of genomics into clinical practice. Genet Med (2010) 2.40
The genomic applications in practice and prevention network. Genet Med (2009) 2.39
A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. Pharmacoeconomics (2010) 2.19
Pharmacogenetic testing: not as simple as it seems. Genet Med (2008) 2.18
Measuring adaptations of motivational interviewing: the development and validation of the behavior change counseling index (BECCI). Patient Educ Couns (2005) 2.17
Genomic profiling to promote a healthy lifestyle: not ready for prime time. Nat Genet (2003) 2.11
The FDA and genomic tests--getting regulation right. N Engl J Med (2015) 2.09
Processes and preliminary outputs for identification of actionable genes as incidental findings in genomic sequence data in the Clinical Sequencing Exploratory Research Consortium. Genet Med (2013) 2.08
Next-generation sequencing in the clinic: are we ready? Nat Rev Genet (2012) 1.95
Stakeholder participation in comparative effectiveness research: defining a framework for effective engagement. J Comp Eff Res (2012) 1.91
Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy (2010) 1.83
The OHRP and SUPPORT. N Engl J Med (2013) 1.78
An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients. Thromb Haemost (2008) 1.76
Value-of-information analysis within a stakeholder-driven research prioritization process in a US setting: an application in cancer genomics. Med Decis Making (2013) 1.70
Design, implementation, and first-year outcomes of a value-based drug formulary. J Manag Care Spec Pharm (2015) 1.67
A model of cost-effectiveness of tissue plasminogen activator in patient subgroups 3 to 4.5 hours after onset of acute ischemic stroke. Ann Emerg Med (2012) 1.58
Cost-effectiveness of peginterferon alpha-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan. J Gastroenterol Hepatol (2007) 1.58
Researcher perspectives on disclosure of incidental findings in genetic research. J Empir Res Hum Res Ethics (2010) 1.55
A risk-benefit analysis of factor V Leiden testing to improve pregnancy outcomes: a case study of the capabilities of decision modeling in genomics. Genet Med (2012) 1.52
University of Washington Twin Registry: construction and characteristics of a community-based twin registry. Twin Res Hum Genet (2006) 1.52
Differential use of available genetic tests among primary care physicians in the United States: results of a national survey. Genet Med (2008) 1.51
Clinical decisions. Screening an asymptomatic person for genetic risk. N Engl J Med (2014) 1.51
Informed Consent in Genome-Scale Research: What Do Prospective Participants Think? AJOB Prim Res (2012) 1.50
Confronting real time ethical, legal, and social issues in the Electronic Medical Records and Genomics (eMERGE) Consortium. Genet Med (2010) 1.47
Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities. Med Decis Making (2010) 1.45
Economic outcome of cardiac CT-based evaluation and standard of care for suspected acute coronary syndrome in the emergency department: a decision analytic model. Acad Radiol (2011) 1.45
Hereditary diffuse gastric cancer: association with lobular breast cancer. Fam Cancer (2008) 1.45
The timing of elective colectomy in diverticulitis: a decision analysis. J Am Coll Surg (2004) 1.45
Screening for the alpha-adducin Gly460Trp variant in hypertensive patients: a cost-effectiveness analysis. Pharmacogenet Genomics (2006) 1.44
Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genet Med (2011) 1.44
Optimizing CAD diagnosis in China with CT angiography. J Cardiovasc Comput Tomogr (2009) 1.43
Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research. Genet Med (2012) 1.39
Current priorities for public health practice in addressing the role of human genomics in improving population health. Am J Prev Med (2011) 1.36
Taking family history seriously. Ann Intern Med (2005) 1.36
Feasibility of incorporating genomic knowledge into electronic medical records for pharmacogenomic clinical decision support. BMC Bioinformatics (2010) 1.32
Diverse perceptions of the informed consent process: implications for the recruitment and participation of diverse communities in the National Children's Study. Am J Community Psychol (2012) 1.28
Trends in death associated with pediatric dental sedation and general anesthesia. Paediatr Anaesth (2013) 1.28
Gene expression profiling and breast cancer care: what are the potential benefits and policy implications? Genet Med (2005) 1.27
Ethical issues in identifying and recruiting participants for familial genetic research. Am J Med Genet A (2004) 1.20
The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med (2004) 1.19
Cost effectiveness of pharmacogenomics: a critical and systematic review. Pharmacoeconomics (2010) 1.19
Offering aggregate results to participants in genomic research: opportunities and challenges. Genet Med (2012) 1.19
A cost-effectiveness analysis of intraoperative cholangiography in the prevention of bile duct injury during laparoscopic cholecystectomy. J Am Coll Surg (2003) 1.18
An economic viewpoint on alternative strategies for identifying persons with hereditary nonpolyposis colorectal cancer. Genet Med (2003) 1.18
Prioritization in comparative effectiveness research: the CANCERGEN Experience. Med Care (2012) 1.17
Return of incidental findings in genomic medicine: measuring what patients value--development of an instrument to measure preferences for information from next-generation testing (IMPRINT). Genet Med (2013) 1.16
Return of results: ethical and legal distinctions between research and clinical care. Am J Med Genet C Semin Med Genet (2014) 1.16
The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer. Value Health (2008) 1.16
NIH State-of-the-Science Conference Statement: Role of active surveillance in the management of men with localized prostate cancer. NIH Consens State Sci Statements (2013) 1.14
Estimating the costs of induced abortion in Uganda: a model-based analysis. BMC Public Health (2011) 1.13
Managing incidental genomic findings: legal obligations of clinicians. Genet Med (2013) 1.11
Pharmacogenomic testing to prevent aminoglycoside-induced hearing loss in cystic fibrosis patients: potential impact on clinical, patient, and economic outcomes. Genet Med (2007) 1.11
Economic analyses of human genetics services: a systematic review. Genet Med (2005) 1.10
Educational needs in genetic medicine: primary care perspectives. Community Genet (2008) 1.09
Pediatricians' experience with and response to parental vaccine safety concerns and vaccine refusals: a survey of Connecticut pediatricians. Public Health Rep (2011) 1.09
Waiving informed consent in newborn screening research: balancing social value and respect. Am J Med Genet C Semin Med Genet (2008) 1.08
Association between the ubiquitin carboxyl-terminal esterase L1 gene (UCHL1) S18Y variant and Parkinson's Disease: a HuGE review and meta-analysis. Am J Epidemiol (2009) 1.08
Cost-effectiveness of pancreatic cancer screening in familial pancreatic cancer kindreds. Gastrointest Endosc (2003) 1.07
A review of selected patient-generated outcome measures and their application in clinical trials. Value Health (2003) 1.07
Breast cancer risk counseling improves women's functioning. Patient Educ Couns (2004) 1.06
Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC). Lung Cancer (2008) 1.06
Will genomics widen or help heal the schism between medicine and public health? Am J Prev Med (2007) 1.06
Anticipating dissemination of cancer genomics in public health: a theoretical approach to psychosocial and behavioral challenges. Ann Behav Med (2007) 1.05
Genetics researchers' and IRB professionals' attitudes toward genetic research review: a comparative analysis. Genet Med (2012) 1.05
Does genomic risk information motivate people to change their behavior? Genome Med (2009) 1.03
Communication, stress and distress: evolution of an individual support programme for medical students and doctors. Med Educ (2005) 1.01
Potential cost-effectiveness of universal access to modern contraceptives in Uganda. PLoS One (2012) 0.98
Stakeholder perspectives on a risk-benefit framework for genetic testing. Public Health Genomics (2010) 0.98
Predictors of recruited melanoma families into a behavioral intervention project. Contemp Clin Trials (2011) 0.98
Primary-care physicians' access to genetic specialists: an impediment to the routine use of genomic medicine? Genet Med (2013) 0.97